BICARA THERAPEUTICS INC (BCAX)
Health Care · NASDAQ
A clinical-stage biopharmaceutical company developing bifunctional therapies that combine EGFR-targeting with tumor microenvironment modulators to treat solid tumors.
What BICARA THERAPEUTICS INC does
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. The company's lead program, ficerafusp alfa, is a bifunctional monoclonal antibody that combines EGFR targeting with a TGF-β ligand trap, designed to enhance drug delivery to the tumor microenvironment while limiting systemic toxicity. Ficerafusp alfa simultaneously blocks cancer cell EGFR survival pathways and immunosuppressive TGF-β signaling to drive immune cell infiltration and anti-tumor responses. The company is advancing ficerafusp alfa in clinical trials for head and neck squamous cell carcinoma and other solid tumors with inadequate tumor penetration and strong biologic rationale for dual EGFR/TGF-β inhibition.
Themes: []
Fundamentals
- Price$29.68 as of 2026-07-09 close
- Market cap$1.9B as of 2026-07-10
- 1-year return+213.1% as of 2026-07-09 close
- ROE-35.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.96 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.